From Mitochondrial Function to Neuroprotection—an Emerging Role for Methylene Blue

Donovan Tucker, Yujiao Lu, Quanguang Zhang

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Methylene blue (MB) is a well-established drug with a long history of use, owing to its diverse range of use and its minimal side effect profile. MB has been used classically for the treatment of malaria, methemoglobinemia, and carbon monoxide poisoning, as well as a histological dye. Its role in the mitochondria, however, has elicited much of its renewed interest in recent years. MB can reroute electrons in the mitochondrial electron transfer chain directly from NADH to cytochrome c, increasing the activity of complex IV and effectively promoting mitochondrial activity while mitigating oxidative stress. In addition to its beneficial effect on mitochondrial protection, MB is also known to have robust effects in mitigating neuroinflammation. Mitochondrial dysfunction has been identified as a seemingly unifying pathological phenomenon across a wide range of neurodegenerative disorders, which thus positions methylene blue as a promising therapeutic. In both in vitro and in vivo studies, MB has shown impressive efficacy in mitigating neurodegeneration and the accompanying behavioral phenotypes in animal models for such conditions as stroke, global cerebral ischemia, Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury. This review summarizes recent work establishing MB as a promising candidate for neuroprotection, with particular emphasis on the contribution of mitochondrial function to neural health. Furthermore, this review will briefly examine the link between MB, neurogenesis, and improved cognition in respect to age-related cognitive decline.

Original languageEnglish (US)
Pages (from-to)5137-5153
Number of pages17
JournalMolecular Neurobiology
Volume55
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Methylene Blue
Electrons
Methemoglobinemia
Carbon Monoxide Poisoning
Neurogenesis
Cytochromes c
Brain Ischemia
Neurodegenerative Diseases
NAD
Cognition
Malaria
Parkinson Disease
Alzheimer Disease
Mitochondria
Oxidative Stress
Coloring Agents
Animal Models
Stroke
Phenotype
Health

Keywords

  • Cognitive enhancement
  • Methylene blue
  • Neurodegenerative disorders
  • Neurogenesis
  • Neuroprotection

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Neurology
  • Cellular and Molecular Neuroscience

Cite this

From Mitochondrial Function to Neuroprotection—an Emerging Role for Methylene Blue. / Tucker, Donovan; Lu, Yujiao; Zhang, Quanguang.

In: Molecular Neurobiology, Vol. 55, No. 6, 01.06.2018, p. 5137-5153.

Research output: Contribution to journalReview article

@article{82ad082f27fb4fa49f3224afd2dd05ab,
title = "From Mitochondrial Function to Neuroprotection—an Emerging Role for Methylene Blue",
abstract = "Methylene blue (MB) is a well-established drug with a long history of use, owing to its diverse range of use and its minimal side effect profile. MB has been used classically for the treatment of malaria, methemoglobinemia, and carbon monoxide poisoning, as well as a histological dye. Its role in the mitochondria, however, has elicited much of its renewed interest in recent years. MB can reroute electrons in the mitochondrial electron transfer chain directly from NADH to cytochrome c, increasing the activity of complex IV and effectively promoting mitochondrial activity while mitigating oxidative stress. In addition to its beneficial effect on mitochondrial protection, MB is also known to have robust effects in mitigating neuroinflammation. Mitochondrial dysfunction has been identified as a seemingly unifying pathological phenomenon across a wide range of neurodegenerative disorders, which thus positions methylene blue as a promising therapeutic. In both in vitro and in vivo studies, MB has shown impressive efficacy in mitigating neurodegeneration and the accompanying behavioral phenotypes in animal models for such conditions as stroke, global cerebral ischemia, Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury. This review summarizes recent work establishing MB as a promising candidate for neuroprotection, with particular emphasis on the contribution of mitochondrial function to neural health. Furthermore, this review will briefly examine the link between MB, neurogenesis, and improved cognition in respect to age-related cognitive decline.",
keywords = "Cognitive enhancement, Methylene blue, Neurodegenerative disorders, Neurogenesis, Neuroprotection",
author = "Donovan Tucker and Yujiao Lu and Quanguang Zhang",
year = "2018",
month = "6",
day = "1",
doi = "10.1007/s12035-017-0712-2",
language = "English (US)",
volume = "55",
pages = "5137--5153",
journal = "Molecular Neurobiology",
issn = "0893-7648",
publisher = "Humana Press",
number = "6",

}

TY - JOUR

T1 - From Mitochondrial Function to Neuroprotection—an Emerging Role for Methylene Blue

AU - Tucker, Donovan

AU - Lu, Yujiao

AU - Zhang, Quanguang

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Methylene blue (MB) is a well-established drug with a long history of use, owing to its diverse range of use and its minimal side effect profile. MB has been used classically for the treatment of malaria, methemoglobinemia, and carbon monoxide poisoning, as well as a histological dye. Its role in the mitochondria, however, has elicited much of its renewed interest in recent years. MB can reroute electrons in the mitochondrial electron transfer chain directly from NADH to cytochrome c, increasing the activity of complex IV and effectively promoting mitochondrial activity while mitigating oxidative stress. In addition to its beneficial effect on mitochondrial protection, MB is also known to have robust effects in mitigating neuroinflammation. Mitochondrial dysfunction has been identified as a seemingly unifying pathological phenomenon across a wide range of neurodegenerative disorders, which thus positions methylene blue as a promising therapeutic. In both in vitro and in vivo studies, MB has shown impressive efficacy in mitigating neurodegeneration and the accompanying behavioral phenotypes in animal models for such conditions as stroke, global cerebral ischemia, Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury. This review summarizes recent work establishing MB as a promising candidate for neuroprotection, with particular emphasis on the contribution of mitochondrial function to neural health. Furthermore, this review will briefly examine the link between MB, neurogenesis, and improved cognition in respect to age-related cognitive decline.

AB - Methylene blue (MB) is a well-established drug with a long history of use, owing to its diverse range of use and its minimal side effect profile. MB has been used classically for the treatment of malaria, methemoglobinemia, and carbon monoxide poisoning, as well as a histological dye. Its role in the mitochondria, however, has elicited much of its renewed interest in recent years. MB can reroute electrons in the mitochondrial electron transfer chain directly from NADH to cytochrome c, increasing the activity of complex IV and effectively promoting mitochondrial activity while mitigating oxidative stress. In addition to its beneficial effect on mitochondrial protection, MB is also known to have robust effects in mitigating neuroinflammation. Mitochondrial dysfunction has been identified as a seemingly unifying pathological phenomenon across a wide range of neurodegenerative disorders, which thus positions methylene blue as a promising therapeutic. In both in vitro and in vivo studies, MB has shown impressive efficacy in mitigating neurodegeneration and the accompanying behavioral phenotypes in animal models for such conditions as stroke, global cerebral ischemia, Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury. This review summarizes recent work establishing MB as a promising candidate for neuroprotection, with particular emphasis on the contribution of mitochondrial function to neural health. Furthermore, this review will briefly examine the link between MB, neurogenesis, and improved cognition in respect to age-related cognitive decline.

KW - Cognitive enhancement

KW - Methylene blue

KW - Neurodegenerative disorders

KW - Neurogenesis

KW - Neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=85028309602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028309602&partnerID=8YFLogxK

U2 - 10.1007/s12035-017-0712-2

DO - 10.1007/s12035-017-0712-2

M3 - Review article

C2 - 28840449

AN - SCOPUS:85028309602

VL - 55

SP - 5137

EP - 5153

JO - Molecular Neurobiology

JF - Molecular Neurobiology

SN - 0893-7648

IS - 6

ER -